Comparative evaluation of VITEK 2® for antimicrobial susceptibility testing of group B Streptococcus | Zendy

Asmaa Tazi | Zendy; Hélène RéglierPoupet | Zendy; Josette Raymond | Zendy; J. Adam | Zendy; Patrick TrieuCuot | Zendy; Claire Poyart | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Comparative evaluation of VITEK 2® for antimicrobial susceptibility testing of group B Streptococcus

Author(s) -

Asmaa Tazi,

Hélène RéglierPoupet,

Josette Raymond,

J. Adam,

Patrick TrieuCuot,

Claire Poyart

Publication year - 2007

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkm098

Subject(s) - penicillin , microbiology and biotechnology , antibiotics , group b , antibiotic resistance , streptococcus agalactiae , biology , streptococcus , antimicrobial , tetracycline , medicine , bacteria , genetics

Intrapartum antibiotic prophylaxis is recommended to prevent neonatal group B streptococcal (GBS) disease in colonized women, and penicillin or aminopenicillin constitute the first-line antibiotics. Most isolates are resistant to tetracycline, and resistance to macrolide-lincosamide-streptogramin (MLS) antibiotics is increasing. Therefore, laboratory testing for MLS resistance in GBS is now recommended for penicillin-allergic patients. The aim of this study was to compare the antimicrobial susceptibility of GBS as determined by the VITEK 2 system (bioMérieux, Marcy l'Etoile, France), agar diffusion methods and PCR-genotypic detection of resistance genes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research